Filter Results
Filter Results
Integrated Biologics (7) Specialized Modalities (6) Advanced Synthesis (2) Corporate (1)
Media Advisory (16) Sustainability (1)
2023 (16)
2023X
Reset Filters
   Loading...
Showing 1‐16 of 16
Media Advisory
14 Nov 2023
Lonza Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency
New cell line designed to help overcome challenges in immunotherapy research and development related to the need for antibody therapeutics to have increased potency Derived...
Media Advisory
24 Oct 2023
Lonza’s Rapid PyroCell® Monocyte Activation Test Systems Make Rabbit-Free Pyrogen Testing Faster, Easier, and More Efficient
Lonza launched PyroCell® MAT Rapid System and PyroCell® MAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine...
Media Advisory
07 Sep 2023
Lonza Upgrades MODA-ES® Module for Enhanced Electronic Batch Record Execution
The MODA-ES® Module v4.0 is an electronic batch record solution that helps pharmaceutical customers to expedite batch release by minimizing paper-based processes The improved...
Media Advisory
30 Aug 2023
Lonza and Vertex Celebrate Groundbreaking of Cell Therapy Manufacturing Facility in Portsmouth (US)
The large-scale facility will support the development and commercialization of the Vertex type 1 diabetes (T1D) cell therapy portfolio At the facility’s groundbreaking event...
Media Advisory
08 Aug 2023
Lonza Launches Nebula® Absorbance Reader for Streamlined Endotoxin and Pyrogen Testing
Lonza adds new Nebula® Absorbance Reader to its portfolio of Lonza-developed and optimized microplate readers for streamlined endotoxin and pyrogen testing The instrument is...
Media Advisory
17 Jul 2023
Lonza Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture
Lonza’s new cell culture media system is designed to optimize the production of therapeutic monoclonal antibodies The two-part production system is proven to yield...
Media Advisory
08 Jun 2023
Lonza Signs Ten-Year Virtual Power Purchase Agreement for Solar Electricity with IGNIS
Lonza Signs Ten-Year Virtual Power Purchase Agreement for Solar Electricity with IGNIS
Media Advisory
16 May 2023
Lonza Launches TheraPEAK® T-VIVO® Cell Culture Medium to Accelerate Cell Therapy Development
Lonza launches the TheraPEAK® T-VIVO® Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing Unlike other...
Media Advisory
04 Apr 2023
Lonza and ABL Bio Collaborate in the Development and Manufacture of Bispecific Antibody Product
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution   Lonza’s DNA-to-IND program helps...
Media Advisory
08 Mar 2023
Lonza Upgrades Powder Characterization Capabilities at Tampa (US) Site
Lonza Tampa (US) upgrades powder characterization capabilities with the addition of universal powder flow testing and automated particle size and shape analysis systems  New...
Media Advisory
13 Feb 2023
Lonza to Expand Early Development Services Offering into North America
A new facility in Cambridge, Massachusetts (US) will open in May 2023, making Lonza’s Early Development Services easily accessible to US-based customers New laboratories will...
Media Advisory
31 Jan 2023
Lonza Celebrates Groundbreaking of New Commercial Drug Product Facility in Stein
Milestone for the development of Lonza’s first large-scale drug product manufacturing facility based in Stein (CH) The facility will complete Lonza’s strategic commitment to...
Media Advisory
30 Jan 2023
Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a Cis-Targeted IL-2 Immunotherapy
Asher Bio’s lead drug candidate AB248, a cis-targeted IL-2 immunotherapy for the treatment of cancer, to be manufactured at Lonza’s site in Visp (CH) Agreement builds upon...
Media Advisory
17 Jan 2023
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox Collaborations further the development of an...
Media Advisory
16 Jan 2023
Lonza Completes Expansion to Solid Form Services Facility at Bend (US) Site
The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules New facility is based at Lonza’s Bend,...
Media Advisory
09 Jan 2023
Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being...